A commonly used drug could dramatically increase survival rates for men who have to fight prostate cancer twice.
The drug, a type of androgen-depleting therapy, is a frontline treatment for men who opt not to have surgery for the cancer. But the new finding indicates it could also be a valuable add-on treatment to surgery if the cancer returns.
